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ABSTRACT
Background The proinfl ammatory and anti-infl ammatory 
role of the sympathetic nervous system in early and 
late infl ammation is an unresolved paradox. A drastic 
loss of sympathetic nerve fi bres in the synovial tissue of 
patients with rheumatoid arthritis (RA) has previously 
been demonstrated. The presence of tyrosine hydroxylase 
(TH)-positive cells in RA and osteoarthritis (OA) has been 
determined, but the role of these cells in infl ammation is 
still unclear.
Objective To characterise TH-positive cells in infl amed 
RA and OA synovial tissue and to study their role in 
infl ammation.
Methods Synovial samples were obtained from 32 
patients with OA and 19 patients with RA and from 10 
control patients. Synovial tissue samples were used 
for immunofl uorescence staining. Synovial cells were 
isolated by tissue digestion and immediately used for cell 
culture. For in vivo experiments, collagen type-II arthritis 
in DBA/1J mice was induced.
Results TH+ cells were present only in infl amed tissue 
and not in controls. Catecholamine-storing vesicles 
and vesicular monoamine transporter 2 (VMAT2) were 
identifi ed in the synovial tissue. Experimental increase of 
cytoplasmic catecholamines by VMAT2 blockade strongly 
reduced tumour necrosis factor (TNF) independently of 
canonical extracellular β-adrenergic signalling. In addition, 
VMAT2 blockade increased cyclic AMP (cAMP) and 
cAMP responsive element binding protein, responsible 
for TNF inhibition. In vivo, appearance of VMAT2 positive 
cells was confi rmed. VMAT2 blockade ameliorated 
infl ammation also in vivo.
Conclusions This study demonstrates that local 
catecholamine-producing cells start to replace 
sympathetic nerve fi bres around the onset of disease, and 
modulation of locally produced catecholamines has strong 
anti-infl ammatory effects in vivo and in vitro.
INTRODUCTION
The role of the sympathetic nervous system (SNS) in 
causing inﬂ ammation is still not  completely under-
stood. Since the 1950s, it has been claimed that sym-
pathetic nerve ﬁ bres  aggravate  inﬂ ammation—for 
example, in rheumatoid  arthritis (RA).1 2 Before 
disease onset, we conﬁ rmed the strong proinﬂ am-
matory inﬂ uence of the SNS in inﬂ ammation.3 4 
Surprisingly, in the chronic phase of arthritis, the SNS 
has a strong anti-inﬂ ammatory role as substantiated 
by chemical SNS blockade.3 Very similar effects 
of SNS were recently described in two models of 
chronic inﬂ ammatory bowel disease.5 The mecha-
nisms behind the transition from proinﬂ ammatory 
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to anti-inﬂ ammatory effects are elusive, but we 
were convinced that they might explain the dual 
role of SNS in inﬂ ammatory diseases.
Nowadays, it is well documented that sympa-
thetic neurotransmitters directly inﬂ uence immune 
cells via adrenergic receptors (reviewed by Kin and 
Sanders 6). Effects of catecholamines on different 
cell types depend on distinct receptor subtypes 
with opposing signalling pathways (summarised 
by Watling and Miller et al 7 8). Stimulation of 
α2-adrenoceptors (α2ARs) decreases cyclic AMP 
and stimulates tumour necrosis factor (TNF), 
whereas binding of βARs leads to cyclic AMP stim-
ulation and downregulation of TNF.9 10 In contrast 
to sympathetic nerve ﬁ bres, the vagus nerve always 
has an important anti-inﬂ ammatory role in arthri-
tis, as well described.11 12 Since norepinephrine (NE) 
demonstrates markedly higher afﬁ nity for αARs 
than βARs, low levels of NE preferentially stimu-
late αARs. These proinﬂ ammatory α-adrenergic 
effects also stimulate pain pathways.13 Under 
 consideration of the rapid loss of sympathetic 
nerve ﬁ bres in inﬂ amed tissue,3 5 8 we and others 
explained the proinﬂ ammatory inﬂ uence of the 
SNS by low  catecholamine concentrations and αAR 
involvement.13 14 However, this does not explain 
the observed anti-inﬂ ammatory effect of the SNS in 
the late phase of arthritis when sympathetic nerve 
ﬁ bres are completely lost and remaining neurotrans-
mitter concentration in the tissue is low.3
In recent years, it became clear that both sym-
pathetic nerve ﬁ bres and immune cells produce 
catecholamines in the periphery.15–18 We also iden-
tiﬁ ed cells positive for tyrosine hydroxylase (TH), 
the key enzyme for catecholamine production, 
only in synovial tissue of patients with chronic 
inﬂ ammation.8 19 The loss of sympathetic nerve 
ﬁ bres and the increase of TH+ cells positively cor-
related with the inﬂ ammation index and with the 
amount of interleukin 6 and interleukin 8 released 
from inﬂ amed tissue.8 19 Catecholamine-producing 
cells can inﬂ uence inﬂ ammation as recently shown 
in acute inﬂ ammatory lung injury.18
The aims of this study were to characterise TH+ 
cells present in the synovial tissue, to demonstrate 
the role of local catecholamine production dur-
ing arthritis and to deﬁ ne the cellular pathway 
involved.
PATIENTS AND METHODS
Patients and control subjects
Nineteen patients with RA and 32 patients with 
osteoarthritis (OA) who underwent knee joint 
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replacement surgery were included without further selection 
(table 1 online supplementary ﬁ le). Control synovial tissue 
samples were obtained from patients with joint trauma during 
routine arthroscopy or open joint surgery for diagnostic and ther-
apeutic procedures (mean age 41±5). All patients were informed 
of the purpose of the study and gave written  consent. The study 
was approved by the ethical committee of the University of 
Regensburg.
Synovial tissue preparation and cell culture
The tissue preparation for histological studies was performed as 
previously described.8
For in vitro cell culture experiments, mixed synovial cells20 
(online supplementary ﬁ gure 1) were isolated by enzymatic tis-
sue digestion as previously described.8 Cells were cultured with 
different substances for 24 h, and then supernatants were col-
lected and frozen until needed for cytokine and catecholamine 
determination. For more details, see online supplementary ﬁ le.
Superfusion technique of synovial tissue
As described previously in detail for spleen slices,21 22 we used 
a superfusion chamber (80 μl) apparatus to superfuse pieces of 
OA and RA synovial tissue with culture medium. At 120 min, 
superfusate was collected in order to measure spontaneous 
 catecholamine release (see below). The superfusate was  collected 
in tubes preﬁ lled with ethylenebis(oxyethylenenitrilo)tetra-ace-
tic acid/glutathione (EGTA/GSH) solution (ﬁ nal concentration 
37 mM EGTA and 30 mM GSH) and immediately frozen.
Blood cell isolation
Blood samples of patients with OA and RA were centrifuged 
to remove plasma. The erythrocytes were lysed with speciﬁ c 
lysis buffer (Qiagen, Hilden, Germany). Isolated blood cells 
were counted and spotted on glass slides at the concentration 
of 10.000 cells/spot using the Cytospin (Cytospin3, Shandon, 
Frankfurt, Germany). Samples were then ﬁ xed with 3.7% form-
aldehyde for 20 min and stored at −20°C until use.
Immunofl uorescence staining of synovial 
tissue and isolated cells
Cryosections (8 μm) of at least three different formaldehyde-
ﬁ xed synovial tissue samples from each patient were used. 
Cultured cells (U937 and THP-1) were spotted on a glass slide 
and ﬁ xed, as described above for blood cells.
Non-speciﬁ c binding sites were blocked with phosphate-buff-
ered saline containing 10% fetal bovine serum, 10% bovine serum 
albumin and 10% normal chicken serum for 45 min at room tem-
perature. The samples were then incubated with the respective 
primary antibody (or with both primary antibodies, for double 
staining) for 3 h at room temperature, washed and then incubated 
with speciﬁ c secondary antibody for 90 min. After 4’-6-diamidi-
no-2-phenylindole staining (Roche, Mannheim, Germany), slides 
were covered with ﬂ uorescence mounting medium (DAKO, 
Hamburg, Germany) and stored at +4°C until microscopy (per-
formed within 4 days). Control staining with the secondary anti-
body alone and with respective isotype controls were carried 
out in parallel and showed no positive staining (supplementary 
ﬁ gure 2). For more details see online supplementary table 2.
Evaluation of positive cells and nerve fi bre density
The density of positive cells and positive nerve ﬁ bres was 
averaged from 17 randomly selected high-power ﬁ elds at a 
 magniﬁ cation of 400× and expressed per square millimetre.
High performance liquid chromatography
Catecholamines in the cells and in the culture medium were 
assayed by high performance liquid chromatography with 
 multi-electrode electrochemical detection, as described 
 previously.23 The chromatograms were collected, stored 
and  processed with the application software Coularray for 
Windows (ESA). Catecholamines were quantiﬁ ed using the 
peak heights of a standard curve generated by injecting known 
samples (3 fmol to 3 pmol), and values were ﬁ nally normalised 
for cell number. Using this method, the detection limit for cat-
echolamines and metabolites was 0.10×10−12 mol/ml.
TNF measurement
Quantiﬁ cation of TNF was performed using Beadlyte cytokine 
assay (Upstate) according to the manufacturer’s protocol by 
Luminex Oosterhout, The Netherlands; (Luminex 100, Software: 
IS2.2). This method allows a sensitive cytokine determination 
even in very small sample volume (<50 μl). Cytokine determina-
tion in each sample was performed in duplicate.
Cell culture of U937 and THP-1
U937 and THP-1 human monocytic cell lines were used as con-
trol for TNF and catecholamine quantiﬁ cation. U937 cells were 
also used for intracellular TNF measurement and TNF mRNA 
evaluation. For more details, see online supplementary ﬁ le.
RNA isolation and real-time PCR
cDNA was converted from 1 μg of total RNA (Invitrogen RT Kit; 
Invitrogen, Groningen, The Netherlands). For quantitative PCR 
(qPCR), 2 μl of cDNA preparation, 2 μl of Primer Assay speciﬁ c 
for human TNF (Quiagen) or 1 μl primers for β-actin (Sigma 
Aldrich, Deisenhofen, Germany) and SybrGreen PCR master mix 
(Quiagen) were applied in a total volume of 20 μl. The PCR prim-
ers and programme used are described in the  supplementary ﬁ le.
The PCR reaction was evaluated by melting curve analysis 
according to the manufacturer’s instructions (LightCycler tech-
nology; Roche). Each qPCR was performed at least in duplicate 
for two sets of RNA preparations.
Animals and arthritis model
For in vivo experiments, collagen type-II arthritis was induced 
in DBA/1J mice. One hind paw was injected with 600 μg reser-
pine or with dimethylsulphoxide (control) (day 0) when swell-
ing reached a score 8 of 12. The swelling score of all paws was 
evaluated daily until day 14 after the ﬁ rst injection. Scoring was 
performed in a blinded manner. For more details about the pro-
cedure, see supplementary ﬁ le.
Evaluation of the presence of vesicular monoamine 
transporter 2+ (VMAT2+) cells in infl amed paws
For the evaluation of VMAT2+ cells in inﬂ amed paws, mice were 
killed at day 0 (ﬁ rst collagen type-II immunisation) and at days 
28 and 60 after the ﬁ rst immunisation. Paws were ﬁ xed for 24 
h with 3.7% formaldehyde and then decalciﬁ ed in RDO (Apex 
Engineering, Aurora, Illinois, USA) for 36 h. Thereafter, they 
were embedded in TissueTek (Sakura Finetek, Alphen aan den 
Rijn, The Netherlands), and quick frozen ﬂ oating on liquid nitro-
gen. All samples were stored at −80°C. Immunoﬂ uorescence 
staining was performed as described above.
Statistical analysis
Two groups were compared by the non-parametric Mann–
Whitney U test (SPSS). The effect of treatment over time in 
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tissue was similar between OA and RA but the concentra-
tion was low (only α-adrenergic effects expected) (ﬁ gure 1B). 
By performing TH staining of nerve ﬁ bres, we found numer-
ous cells positive for this enzyme (ﬁ gure 1C). Importantly, 
no TH+ cells were found in trauma scontrols. The density 
of TH+ cells was higher in RA than in OA (ﬁ gure 1C). This 
may explain the similar release of NE from RA and OA tissue 
(ﬁ gure 1B). Since TH+ cells might enter the tissue after circu-
lation in the blood, the presence of TH+ cells in blood was 
tested in the same patients. The number of TH+ cells detect-
able in the blood was small and similar in trauma controls, 
RA and OA (ﬁ gure 1D).
animal experiments in vivo (ﬁ gure 5D, E) was tested using the 
General Linear Model analysis (GLM, SPSS, version 16.0). A p 
value of ≤0.05 was considered signiﬁ cant.
RESULTS
Nerve fi bre density and presence of catecholamine-producing 
cells in infl amed tissue
The density of sympathetic TH+ nerve ﬁ bres was drastically 
reduced in patients with RA compared with trauma controls and 
patients with OA (ﬁ gure 1A).
Despite a smaller number of sympathetic nerve ﬁ bres in 
RA synovial tissue, the amount of NE released from the 
Figure 1 Characterisation of tyrosine hydroxylase (TH)-positive synovial cells in patient material. (A) Sympathetic nerve fi bre density in synovial 
tissue of control subjects (Co, after trauma surgery), osteoarthritis (OA) and rheumatoid arthritis (RA) synovial tissue. (B) Concentration of 
norepinephrine in superfusate of OA and RA synovial tissue. (C) Density of TH+ cells in synovial tissue. Left panel: immunofl uorescence staining. 
No TH+ cells were found in control subjects; right panel: quantifi cation of TH+ cell density in OA and RA. (D) TH+ cells in the blood. (E–K) 
Immunofl uorescence double staining of TH (green) and different markers of synovial/immune cells (red). CD163 in E, CD3 in F, CD19 in G, prolyl-4-
hydroxylase in H, elastase in I, tryptase in J and vesicular monoamine transporter 2 (VMAT2) in K. Arrows indicate double-positive cells (yellow 
colour). (L–N) Density of synovial cells positive for dopamine-β-hydroxylase (DBH) (in panel L), DOPA decarboxylase (in panel M) and phenyl-
ethanolamine-N-methyl-transferase (PNMT) (in panel N). Left panel: red immunofl uorescence staining; right panel: quantifi cation of cell density in OA 
and RA synovial tissue. NS, non-signifi cant.
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Characterisation of TH+ cells
In OA and RA synovial tissue, we found double staining of TH 
together with CD163+ (macrophages), CD19+ (B cells), or prolyl-
4-hydroxylase (ﬁ broblasts), but CD3+ T cells were not  positive 
for TH (ﬁ gure 1E–H). In patients with RA only, we found some 
mast cells and neutrophils positive for TH (ﬁ gure 1I, J). TH+ 
cells were also positive for VMAT2, which is indicative of cat-
echolamine storage in intracellular vesicles (ﬁ gure 1K).
In order to demonstrate that TH+ cells enable catecholamine 
generation, we performed immunoﬂ uorescence staining for 
other enzymes involved in catecholamine synthesis. The num-
ber of cells positive for dopamine-β-hydroxylase (DBH) and 3,4-
dihydroxyphenylalanine (DOPA) decarboxylase were higher in 
RA than in OA (ﬁ gure 1L, M), whereas the density of phenyl-
ethanolamine-N-methyltransferase+ cells was similar in the two 
groups (ﬁ gure 1N). The number of cells positive for DBH and 
DOPA-decarboxylase was similar to the number of TH+ cells 
(ﬁ gure 1L, M versus ﬁ gure 1C).
Locally produced catecholamines have very 
little extracellular effects on TNF secretion
After 24 h of culture, catecholamines were present in super-
natants of isolated synovial cells. There was no difference in 
levels of dopamine, NE and epinephrine release between OA 
and RA cell cultures (ﬁ gure 2A–C). As further demonstration 
that TH+ cells really produce catecholamines, we incubated 
synovial cells with labelled [14C]L-tyrosine and detected the 
presence of labelled catecholamine metabolite homovanillic 
acid in cell lysates after 24 h of culture (for more details, see 
supplementary ﬁ le).
In further analyses, the presence and function of adrenergic 
receptors was investigated. In OA and RA synovial tissue, the 
number of α1AR-positive cells did not differ between the two 
groups, but the density of positive cells tended to be higher in 
patients with RA (ﬁ gure 2D). Blockade of α1ARs with benox-
athian induced a slight reduction of TNF secretion in OA but 
not in more inﬂ amed cells of patients with RA (ﬁ gure 2E). No 
differences were detected for the density of α2AR+ cells in OA 
and RA (ﬁ gure 2F). Blockade of α2ARs did not alter TNF secre-
tion (ﬁ gure 2G). For β2ARs, no differences were found for the 
density of positive cells in patients with OA and RA, although 
the number of β2AR cells tended to be lower in patients with 
RA (ﬁ gure 2H). Blockade of βARs with nadolol did not alter TNF 
secretion (ﬁ gure 2I).
An increase of cytoplasmic catecholamines 
strongly inhibits TNF secretion
The density of VMAT2+ cells was ﬁ ve times higher in RA 
than in OA (ﬁ gure 3A). However, the density of catechol-O-
 methyltransferase + (COMT+) cells was similar in the two 
groups (ﬁ gure 3B).
Binding of VMAT2 by reserpine avoids catecholamine stor-
age in vesicles and increases cytoplasmic catecholamine levels 
for a few hours (one-shot effect).24 After treatment with reser-
pine, we observed a strong dose-dependent inhibition of TNF 
secretion, both, in OA and RA cells (ﬁ gure 3C). Similar dose-
 dependent TNF-inhibiting effects were obtained by treating 
cells with the COMT inhibitor OR486 (ﬁ gure 3D). In combi-
nation  experiments with reserpine and OR486, a still stronger 
inhibition of TNF secretion, even at the lowest concentration of 
reserpine, was observed (ﬁ gure 3E).
In further experiments, the site of action of catecholamines 
was tested. Synovial cells were treated with reserpine and OR486 
in combination with the hydrophilic βAR antagonist nadolol, 
which does not pass the cell membrane. Reserpine effects on 
TNF were not altered in the presence of nadolol (ﬁ gure 3F), dem-
onstrating that catecholamines released from vesicles do not act 
extracellularly through canonical β2ARs.
Mechanism of action of cytoplasmic catecholamines
Since it is difﬁ cult to get large numbers of primary cells from 
patients with RA and OA, we performed further experiments 
with the human monocytic cell lines U937. After stimulation 
with phorbol myristate acetate and lipopolysaccharide, U937 
expressed TH and VMAT2 (ﬁ gure 4A, B), and they produced cat-
echolamines in a similar concentration range like primary cells 
(data not shown). Moreover, reserpine inhibited TNF secretion 
in stimulated U937 cells similarly as in primary cells (ﬁ gure 4C).
To investigate whether TNF inhibition was due to cate-
cholamine release into the cytoplasm and not to an unspeciﬁ c 
effect of reserpine, the human monocytic cell line THP-1 was 
tested. In contrast to U937, this cell line was negative for TH 
and VMAT2 (ﬁ gure 4D, E). However, THP-1 cells produced TNF 
after stimulation with lipopolysaccharide (ﬁ gure 4F). Reserpine 
treatment of stimulated THP-1 did not alter TNF secretion into 
supernatants (ﬁ gure 4F). These results demonstrate that reser-
pine speciﬁ cally inhibits TNF by catecholamine-dependent 
effects.
The strong decrease of TNF in the supernatants after reserpine 
treatment might be due to cytoplasmic accumulation of TNF. 
This was ruled out since the TNF level in U937 cell lysates was 
lower after reserpine treatment than in controls (ﬁ gure 4G). In 
addition, reserpine treatment decreased TNF mRNA after 24 h 
compared with controls (ﬁ gure 4H).
Effects of cytoplasmic increase of catecholamine 
on infl ammation in vivo
Owing to the strong effects of reserpine on TNF secretion in 
vitro, we wanted to test if manipulation of cytoplasmic cat-
echolamines is effective in vivo. Collagen type-II arthritis 
was induced in DBA/1J mice. In arthritic animals, as shown 
in ﬁ gure 5A–C, VMAT2+ cells appear in the joints of DBA/1J 
arthritic mice. These cells are absent at the time of immunisa-
tion  (ﬁ gure 5A) but are detectable 28 days after immunisation at 
disease onset (ﬁ gure 5B). Importantly, the number of VMAT2+ 
cells in joints greatly increased 60 days after immunisation in the 
chronic phase of arthritis (ﬁ gure 5C).
The local treatment with reserpine ameliorated the clinical 
score compared with control mice (ﬁ gure 5D), This positive 
effect already appeared 3 days after the ﬁ rst injection of reser-
pine, and the beneﬁ cial effect was stable until day 14 after the 
ﬁ rst injection (ﬁ gure 5D). Importantly, reserpine only demon-
strated local effects because there was no inﬂ uence on untreated 
paws (ﬁ gure 5E).
DISCUSSION
This study demonstrates the presence of catecholamine-pro-
ducing cells in the synovial tissue during arthritis. These cells 
are not present in control tissue, suggesting that they are related 
to chronic inﬂ ammation. Catecholamine-producing peripheral 
blood cells were described earlier.15 16 18 23 They also appear 
in the peripheral blood of patients with multiple sclerosis,25 
and these cells can change catecholamine production depend-
ing on disease activity.26 In patients with RA, who markedly 
lose  sympathetic nerve ﬁ bres, the density of catecholamine-
producing cells was higher than in patients with OA, who do 
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Figure 2 Extracellular effects of locally produced catecholamines. (A–C) Quantifi cation of dopamine (in panel A), norepinephrine (in panel B) and 
epinephrine (in panel C) released by isolated synovial cells after 24 h of cell culture. (D, F, H) Density of α1-adrenoceptor (α1AR) (D), α2AR (F) 
and β2AR (H). Positive cells in synovial tissue from patients with osteoarthritis (OA) and RA. Left panel: immunofl uorescence staining; right panel: 
quantifi cation of positive synovial cells. (E) Tumour necrosis factor (TNF) secretion after blockade of α1AR by benoxathian. (G) TNF secretion after 
blockade of α2AR by yohimbine. (I) TNF secretion after blockade of β2AR by nadolol.
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not lose sympathetic innervation. Of interest, different cells 
in OA and RA synovial tissue can produce catecholamines—
ﬁ broblasts, macrophages, B cells, mast cells and granulocytes. 
It seems that many different cells switch-on the catecholamine-
producing machinery in a coordinated fashion when inﬂ amma-
tion starts and sympathetic nerve ﬁ bres get lost. As TH+ cells 
were not increased in OA and RA blood samples, we believe 
that cells switch-on catecholamine production only locally in 
the inﬂ amed area.
In order to understand the role of locally produced cat-
echolamines on inﬂ ammation, we analysed the effects of AR 
blockade on cytokine release. Although αARs and βARs are 
present in the synovial tissue, blockade with speciﬁ c antagonists 
did not strongly alter cytokine release, suggesting that locally 
produced catecholamines act intracellularly or via non-canonical 
pathways. Blockade of catecholamine storage into vesicles by 
reserpine caused a very strong and speciﬁ c inhibition of TNF 
mRNA and TNF protein from cells of patients with OA and RA, 
which was independent of canonical extracellular βAR. TNF 
inhibition after reserpine was even stronger when  catecholamine 
degradation by COMT was blocked. Experiments performed 
using two different human cell lines demonstrated that  reserpine 
effects are due to intracellular catecholamine release and are not 
an unspeciﬁ c effect of reserpine on TNF.
These positive effects of the cytoplasmic catecholamine 
increase prompted us to test the principle in vivo. It was found 
that local treatment with reserpine markedly reduced inﬂ am-
mation without causing systemic side effects in the animals. As 
reserpine has a longlasting effect in vivo, only two injections 
were necessary to obtain strong anti-inﬂ ammatory effects. As 
cells start producing catecholamines after onset of disease, we 
infer that the proinﬂ ammatory effect of late sympathectomy 
already described3 is due to chemical destruction of cate-
cholamine-producing cells.
Figure 3 Effects of locally produced catecholamines after reserpine treatment. (A, B) Presence of vesicular monoamine transporter 2 (VMAT2) 
(A) and catechol-O-methyltransferase (COMT) (B) positive cells in osteoarthritis/rheumatoid arthritis (OA/RA) synovial tissue. Left panel: 
immunofl uorescence staining; right panel: quantifi cation of positive synovial cells. (C) Tumour necrosis factor (TNF) secretion after blockade of VMAT2 
by reserpine (Res). (D) TNF secretion after 24 h of COMT inhibition with different concentrations of OR486. (E) Combined treatment with reserpine and 
OR486. (F) Combined treatment with reserpine, OR486 and nadolol (Nad).
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Figure 4 Infl uence of increased cytoplasmic catecholamines. (A–B) Immunofl uorescence of U937 cells after phorbol myristate acetate and 
lipopolysaccharide (LPS) stimulation. (A) Tyrosine hydroxylase (TH) staining; (B) vesicular monoamine transporter 2 (VMAT2) staining; (C) 24 h 
Reserpine treatment of U937 cells (n=10). (D,E) Immunofl uorescence of THP-1 cells after LPS stimulation. (D) TH staining; (E) VMAT2 staining; (F) 24 
h Reserpine treatment of THP-1 cells (n=6). (G) Intracellular tumour necrosis factor (TNF) measured in U937 cells after 24 h of reserpine treatment 
(n=10). (H) TNF mRNA content after 1 h or 24 h of reserpine treatment, measured by quantitative PCR (n=6). Control box plot represents mRNA 
values of untreated cells after 1 h and 24 h.
Figure 5 Effects of cytoplasmic increase of catecholamine on infl ammation in vivo. (A–C) Immunofl uorescence staining of vesicular monoamine 
transporter 2 (VMAT2) in immunised DBA/1J mice at different time points in relation to immunisation. (A) Day of immunisation. (B) Day 28 after 
immunisation. (C) Day 60 after immunisation demonstrates many VMAT2+ cells in infl amed tissue. (D) Evaluation of joint swelling in one hind paw 
after treatment with reserpine (Res; green line) or dimethylsulphoxide (DMSO; control, red line). Arrows indicate injection days. Statistical analysis 
(general linear model) showed a signifi cant difference between the two curves (p<0.001). Day 0 is the day on which score 8 was reached. (E) 
Evaluation of joint swelling in untreated paws. The sum score of the three untreated extremities was calculated in every mouse (arrows indicate 
injection days of treated paw, see (F)).
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In conclusion, this study demonstrates for the ﬁ rst time that 
peripheral cells start producing catecholamines during chronic 
inﬂ ammation, and the increase of cytoplasmic catecholamines 
has strong anti-inﬂ ammatory effects in vitro and in vivo. 
Therefore, modulation of catecholamine-producing cells could 
be used as a new therapeutic target in arthritis.
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